动物保健公司Zoetis Inc.(ZTS)盘前股价一度大跌5.96%,引发市场关注。分析人士认为,这与公司旗舰狗骨关节炎止痛药Librela本季度销售疲软有关。
公司第三季度财报显示,Librela本季度销售额为1.17亿美元,较上季度基本持平,低于市场预期约1000万美元。投资者担忧该产品缺乏增长动力,加剧了对其未来销售前景的疑虑,这可能是导致Zoetis股价短线回落的主因。
但另一方面,Zoetis第三季度整体业绩实际上远超华尔街预期,公司还上调了全年利润和收入指引。除Librela外,其他主力产品如关节炎治疗新药Solensia等销售表现强劲。这反映出公司基本面依然向好,长期前景不容忽视。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.